EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, Ann Rheum Dis. juin, vol.76, issue.6, pp.960-77, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01778213
Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate, Scand J Clin Lab Invest. avr, vol.78, issue.1-2, pp.62-69, 2018. ,
The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis, Scand J Rheumatol, vol.20, issue.2, pp.74-82, 1991. ,
Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases, Rheumatol Oxf Engl. avr, vol.49, issue.4, pp.671-82, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00527450
Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen, Eur J Biochem. 15 juill, vol.134, issue.1, pp.1-6, 1983. ,
Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study, PLoS ONE, issue.8, p.12, 2017. ,
Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate, J Rheumatol. avr, vol.43, issue.4, pp.731-738, 2016. ,
,
, Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis, Ann Rheum Dis. août, vol.66, issue.8, pp.1093-1100, 2007.
,
, Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis, Ann Rheum Dis. janv, vol.69, issue.1, pp.150-154, 2010.
,
, MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, Ann Rheum Dis. mars, vol.74, issue.3, pp.499-505, 2015.
,
, Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis, Ann Rheum Dis. déc, vol.76, issue.12, pp.2031-2038, 2017.
Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis, Arthritis Res Ther, vol.12, issue.1, p.3, 2017. ,
,
Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants ,
, Rheumatol Oxf Engl. déc, vol.54, issue.12, pp.2239-2282, 2015.
Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors, Arthritis Care Res, vol.68, issue.7, pp.899-906, 2016. ,
Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases, J Rheumatol. avr, vol.21, issue.4, pp.733-741, 1994. ,
Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis, Arthritis Res Ther. 15 sept, vol.17, p.252, 2015. ,
Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission, PloS One, vol.11, issue.11, p.165498, 2016. ,
,
Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity, Arthritis Res Ther, vol.08, issue.1, p.160, 2016. ,
The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab, Arthritis Res Ther, vol.13, issue.5, p.178, 2011. ,
The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort, Rheumatol Oxf Engl, vol.01, issue.6, pp.1019-1043, 2017. ,
Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab, Scand J Rheumatol. juill, vol.45, issue.4, pp.274-81, 2016. ,
Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial, Value Health J Int Soc Pharmacoeconomics Outcomes Res. avr, vol.20, issue.4, pp.577-85, 2017. ,
Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study), Ann Rheum Dis. janv, vol.75, issue.1, pp.59-67, 2016. ,
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study, Ann Rheum Dis. juill, vol.69, issue.7, pp.1286-91, 2010. ,
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study, Ann Rheum Dis. févr, vol.74, issue.2, pp.389-95, 2015. ,
,
, Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry, Ann Rheum Dis. juin, vol.74, issue.6, pp.1150-1155, 2015.
Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis, Rheumatol Oxf Engl. août, vol.54, issue.8, pp.1408-1422, 2015. ,
,
Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment, BMC Rheumatol, vol.3, p.3, 2019. ,
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study, Ann Rheum Dis. janv, vol.75, issue.1, pp.45-51, 2016. ,
,
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study, Ann Rheum Dis. févr, vol.70, issue.2, pp.315-324, 2011. ,
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients Références ,
Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review, Semin Arthritis Rheum. déc, vol.36, issue.3, pp.182-190, 2006. ,
The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry, Rheumatol Oxf Engl. juill, vol.47, issue.7, pp.1088-92, 2008. ,
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score, Arthritis Res Ther, vol.7, issue.4, pp.796-806, 2005. ,
The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis, J Immunol Baltim Md, vol.175, issue.9, pp.5575-80, 1950. ,
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis, Arthritis Res Ther, vol.8, issue.2, p.40, 2006. ,
Linkage of cytokine genes to rheumatoid arthritis. Evidence of genetic heterogeneity, Ann Rheum Dis. juin, vol.57, issue.6, pp.361-366, 1998. ,
,
Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins, Arthritis Rheum, vol.52, issue.11, pp.3433-3441, 2005. ,
Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile, Ann Rheum Dis. mai, vol.72, issue.5, pp.652-660, 2013. ,
Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors?, Curr Opin Rheumatol. juill, vol.26, issue.4, pp.424-433, 2014. ,
Epigenetic modifications in rheumatoid arthritis, a review, Curr Opin Pharmacol. juin, vol.13, issue.3, pp.420-425, 2013. ,
,
, Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy, J Exp Med. 2 août, vol.200, issue.3, pp.277-85, 2004.
B-cell targeting in rheumatoid arthritis and other autoimmune diseases, Nat Rev Immunol. mai, vol.6, issue.5, pp.394-403, 2006. ,
Crossroads of B cell activation in autoimmunity: rationale of targeting B cells ,
, J Rheumatol Suppl. mai, vol.77, pp.3-11, 2006.
The synovium as a privileged site in rheumatoid arthritis: cadherin-11 as a dominant player in synovial pathology, Best Pract Res Clin Rheumatol. déc, vol.25, issue.6, pp.767-77, 2011. ,
Molecular and cellular basis of rheumatoid joint destruction, Immunol Lett. 15 juill, vol.106, issue.1, pp.8-13, 2006. ,
, , 2010.
League Against Rheumatism collaborative initiative, Arthritis Rheum. sept, vol.62, issue.9, pp.2569-81, 2010. ,
,
, Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage, Ann Rheum Dis. févr, vol.62, issue.2, pp.261-264, 2000.
A simplified disease activity index for rheumatoid arthritis for use in clinical practice, Rheumatol Oxf Engl. févr, vol.42, issue.2, pp.244-57, 2003. ,
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, Ann Rheum Dis. juin, vol.76, issue.6, pp.960-77, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01778213
Economic consequences and potential benefits, Best Pract Res Clin Rheumatol. août, vol.25, issue.4, pp.607-631, 2011. ,
Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial, Value Health J Int Soc Pharmacoeconomics Outcomes Res. avr, vol.20, issue.4, pp.577-85, 2017. ,
The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials, Am J Med. déc, vol.127, issue.12, pp.1208-1240, 2014. ,
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis, Lancet Lond Engl. 18 juill, vol.386, issue.9990, pp.258-65, 2015. ,
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis, Ann Rheum Dis, vol.70, issue.11, pp.1895-904, 2011. ,
Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors, Ann Rheum Dis. déc, vol.71, issue.12, p.2, 2012. ,
Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study), Ann Rheum Dis. janv, vol.75, issue.1, pp.59-67, 2016. ,
,
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial, BMJ. 9 avr, vol.350, p.1389, 2015. ,
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study, Ann Rheum Dis. janv, vol.75, issue.1, pp.45-51, 2016. ,
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis, Arthritis Rheumatol Hoboken NJ, vol.69, issue.10, pp.1937-1985, 2017. ,
,
, Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial, Lancet Lond Engl. 16 mars, vol.381, issue.9870, pp.918-947, 2013.
Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis ,
, Ann Rheum Dis. janv, vol.75, issue.1, pp.52-60, 2016.
Sustained remission with etanercept tapering in early rheumatoid arthritis, N Engl J Med, vol.371, pp.1781-92, 2014. ,
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis ,
, Ann Rheum Dis. mars, vol.74, issue.3, pp.564-572, 2015.
Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis, Ann Rheum Dis, vol.77, issue.4, pp.515-537, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01740261
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study, Ann Rheum Dis. juill, vol.69, issue.7, pp.1286-91, 2010. ,
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study, Ann Rheum Dis. févr, vol.74, issue.2, pp.389-95, 2015. ,
,
, Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry, Ann Rheum Dis. juin, vol.74, issue.6, pp.1150-1155, 2015.
Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis, Rheumatol Oxf Engl. août, vol.54, issue.8, pp.1408-1422, 2015. ,
,
Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment, BMC Rheumatol, vol.3, p.3, 2019. ,
,
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study, Ann Rheum Dis. févr, vol.70, issue.2, pp.315-324, 2011. ,
Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement, Expert Opin Drug Metab Toxicol. juin, vol.13, issue.6, pp.597-604, 2017. ,
Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study, Ann Rheum Dis. 2 mai, 2019. ,
,
Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment, PloS One, vol.13, issue.5, p.192425, 2018. ,
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment, Ann Rheum Dis. sept, vol.75, issue.9, pp.1637-1681, 2016. ,
Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation, Arthritis Care Res, vol.66, issue.10, pp.1576-81, 2014. ,
Tapering and discontinuation of TNF-? blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission, Arthritis Res Ther. 3 févr, vol.18, p.39, 2016. ,
Functions of S100 proteins, Curr Mol Med. janv, vol.13, issue.1, pp.24-57, 2013. ,
The S100 family of EF-hand calcium-binding proteins: functions and pathology, Trends Biochem Sci. avr, vol.21, issue.4, pp.134-174, 1996. ,
Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway, J Biol Chem. 4 avr, vol.272, issue.14, pp.9496-502, 1997. ,
Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells, J Biol Chem. 25 avr, vol.266, issue.12, pp.7706-7719, 1991. ,
S100 protein subcellular localization during epidermal differentiation and psoriasis, J Histochem Cytochem Off J Histochem Soc. mai, vol.51, issue.5, pp.675-85, 2003. ,
Oxidative modifications of DAMPs suppress inflammation: the case for S100A8 and S100A9, Antioxid Redox Signal, vol.15, issue.8, pp.2235-2283, 2011. ,
The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins, J Mol Biol. 27 juill, vol.370, issue.5, pp.887-98, 2007. ,
,
, Extracellular MRP8/14 is a regulator of ?2 integrin-dependent neutrophil slow rolling and adhesion, Nat Commun. 20 avr, vol.6, p.6915, 2015.
Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis, Ann Rheum Dis. déc, vol.67, issue.12, pp.1750-1758, 2008. ,
Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen, Eur J Biochem. 15 juill, vol.134, issue.1, pp.1-6, 1983. ,
Molecular interface of S100A8 with cytochrome b558 and NADPH oxidase activation, PloS One, vol.7, issue.7, p.40277, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00816899
,
, Calprotectin discriminates septic arthritis from pseudogout and rheumatoid arthritis, Rheumatol Oxf Engl. 28 mars, 2019.
The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis, Scand J Rheumatol, vol.20, issue.2, pp.74-82, 1991. ,
Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity, J Rheumatol. juin, vol.19, issue.6, pp.859-62, 1992. ,
Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab, Scand J Rheumatol. juill, vol.45, issue.4, pp.274-81, 2016. ,
Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis, Scand J Rheumatol. juin, vol.37, issue.3, pp.179-82, 2008. ,
S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis, Korean J Intern Med. janv, vol.29, issue.1, pp.12-21, 2014. ,
Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate, Scand J Clin Lab Invest. avr, vol.78, issue.1-2, pp.62-69, 2018. ,
Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study, PLoS ONE, issue.8, p.12, 2017. ,
A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis, J Rheumatol, vol.16, issue.11, pp.1416-1436, 1989. ,
Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors, Arthritis Care Res, vol.68, issue.7, pp.899-906, 2016. ,
Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate, J Rheumatol. avr, vol.43, issue.4, pp.731-738, 2016. ,
,
, MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, Ann Rheum Dis. mars, vol.74, issue.3, pp.499-505, 2015.
,
, Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis, Ann Rheum Dis. janv, vol.69, issue.1, pp.150-154, 2010.
Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis, Arthritis Res Ther, vol.12, issue.1, p.3, 2017. ,
,
, Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis, Ann Rheum Dis. déc, vol.76, issue.12, pp.2031-2038, 2017.
,
, Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis, Ann Rheum Dis. août, vol.66, issue.8, pp.1093-1100, 2007.
Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases, J Rheumatol. avr, vol.21, issue.4, pp.733-741, 1994. ,
Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein, Clin Rheumatol. août, vol.37, issue.8, pp.2055-62, 2018. ,
,
Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants ,
, Rheumatol Oxf Engl. déc, vol.54, issue.12, pp.2239-2282, 2015.
,
Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up ,
, Semin Arthritis Rheum, vol.47, issue.3, pp.303-312, 2017.
Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis, Arthritis Res Ther. 15 sept, vol.17, p.252, 2015. ,
The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab, Arthritis Res Ther, vol.13, issue.5, p.178, 2011. ,
Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission, PloS One, vol.11, issue.11, p.165498, 2016. ,
,
Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity, Arthritis Res Ther, vol.08, issue.1, p.160, 2016. ,
Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study, Clin Exp Rheumatol. juin, vol.37, issue.3, pp.429-465, 2019. ,
Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach, PloS One, vol.9, issue.12, p.115800, 2014. ,
The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort, Rheumatol Oxf Engl, vol.01, issue.6, pp.1019-1043, 2017. ,
,
, Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis. Comment on « Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis, Ann Rheum Dis, vol.77, issue.12, p.84, 2018.
Clinical Significance of Myeloid-Related Protein 8/14 as a Predictor for Biological Treatment and Disease Activity in Rheumatoid Arthritis, Ann Clin Lab Sci. janv, vol.48, issue.1, pp.63-71, 2018. ,
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis, Arthritis Res Ther. 7 août, vol.17, 0200. ,
Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial, JAMA. 05, vol.321, issue.5, pp.461-72, 2019. ,
Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis, Scand J Clin Lab Invest. avr, vol.78, issue.1-2, pp.102-110, 2018. ,
Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits, Ann Clin Biochem. janv, vol.50, pp.53-61, 2013. ,